Misonidazole Reduces Blood Flow in Tumors
Author Information
Author(s): J.C. Murray, V.S. Randhawa
Primary Institution: Cancer Research Campaign, Gray Laboratory
Hypothesis
The study aims to determine the effects of misonidazole on blood flow and vascular volume in murine tumors and normal tissues.
Conclusion
Misonidazole significantly decreases blood flow in murine tumors, which may have important implications for its use as a chemosensitizer.
Supporting Evidence
- Misonidazole at doses of 500 mg/kg or greater decreased blood flow in both tumors by up to 60% within 2 hours.
- Flow remained reduced for up to 24 hours in tumors, while normal tissues showed recovery.
- Significant changes in blood flow were observed in the SaFA and CaNT tumors after MISO treatment.
Takeaway
Misonidazole is a drug that can make tumors less able to get blood, which might help other cancer treatments work better.
Methodology
Mice were treated with misonidazole, and blood flow and vascular volume were measured using various techniques including 86RbCl extraction and 51Cr-labelled red blood cells.
Limitations
The study primarily uses murine models, which may not fully represent human responses.
Participant Demographics
WHT/Gy and CBA/Ht mice were used in the experiments.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website